middle.news
How Cleo Diagnostics Expanded Its Ovarian Cancer Test Ahead of FDA Submission
8:38am on Monday 23rd of March, 2026 AEDT
•
Healthcare
Read Story
How Cleo Diagnostics Expanded Its Ovarian Cancer Test Ahead of FDA Submission
8:38am on Monday 23rd of March, 2026 AEDT
Key Points
Biomarker panel expanded to eight markers for improved robustness
Optimised for high-throughput Ella™ platform to enable scalability
Manufacturing agreement with experienced partner expected imminently
Test kit production to begin supporting FDA analytical validation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cleo Diagnostics (ASX:COV)
OPEN ARTICLE